Lexaria’s patented DehydraTECH(TM)-CBD achieved promising results for diabetes control and weight loss in animals during the pre-clinical animal study DIAB-A22-1
The weight loss drug market was valued at $1.90 billion in 2021 and is expected to reach $13.26 billion by 2029, growing at a CAGR of 24.7%
Many drugs used to control diabetes have produced results in managing obesity, which Lexaria plans to leverage with its DehydraTECH(TM) technology
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, recently announced its intent to conduct a human clinical study to examine its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for diabetes control and weight loss. The company has already completed a pre-clinical diabetes study in animals, which supports its advancement to human trials for diabetes control and weight loss (https://cnw.fm/H1XXZ).
Lexaria had announced in two prior press releases, on March 2 and June 16, that its pre-clinical diabetes study DIAB-A22-1 in obese diabetic-conditioned animals, that DehydraTECH-CBD had achieved the following:
Lowered blood glucose levels by 19.9% (p<0>
Lowered overall body weight by 7% sustained over eight weeks
Witnessed a statistically significant increase in locomotor activity (p<0>
Lowered triglyceride levels by more than 25% (p<0>
Lowered blood urea nitrogen levels by 27.9% (p<0>
Based on these successful pre-clinical results, the management of Lexaria has decided to undertake a human diabetes clinical study to investigate whether any of these improvements will also be evidenced in humans. Lexaria is currently designing the study, which will be followed by submission to an independent review board to gain necessary approvals.
According to the Centers for Disease Control (“CDC”), managing one’s blood sugar levels is important to avoid diabetes-related conditions, including vision loss, heart disease, and kidney disease (https://cnw.fm/cgbJX). Generic CBD studies, mainly conducted in animals, indicate that it may be ineffective in controlling blood sugar. Lexaria hopes to study whether the DehydraTECH-CBD formulation provides additional insight into human blood sugar control. The company is encouraged by DehydraTECH-CBD’s ability to reduce animal blood sugar levels and believes it warrants additional investigation.
The DehydraTECH technology is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active pharmaceutical ingredients (“APIs”). DehydraTECH increases effectiveness and improves the way these APIs enter the bloodstream. The benefits of ingesting a DehydraTECH-enabled drug or consumer product include the following:
Speeds up delivery with effects of the product felt in minutes
Increases bioavailability due to its effectiveness in delivering a drug into the bloodstream
Increases brain absorption, with animal testing evidencing higher drug quantities delivered across the blood-brain barrier
Improved drug potency, with more of the drug available to the body, requiring lower dosages
Reduced drug administration costs, meaning that lower dosages require less drug cost overall
Mask unwanted tastes and reduces or eliminate the need for sweeteners
The company has also collaborated with the National Research Council (“NRC”), the Canadian government’s premier research and technology organization. DehydraTECH is covered by over 30 granted patents, with more pending worldwide. The patent protection includes formulations for specific delivery of cannabinoids, antiviral drugs, nicotine and more.
Many drugs used to control human blood glucose levels have shown promising weight loss results. The weight loss drug market was valued at $1.90 billion in 2021 and is expected to reach $13.26 billion by 2029, growing at a CAGR of 24.7% (https://cnw.fm/of7Pg). The market is growing due to the public’s growing interest in how obesity contributes to other health problems. Lexaria is positioning itself to potentially penetrate this market with its human-based clinical trial of DehydraTECH-CBD and diabetes control.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
(Globe Newswire) Chicago and Vancouver — RISE Dispensaries, a rapidly growing cannabis retail chain owned by Green Thumb Industries Inc., today unveiled its refreshed retail brand identity. As the brand nears its seventh anniversary, RISE has debuted an inspired brand vision that embodies the Company’s desire to galvanize the cannabis community to join its movement to democratize cannabis access.
The refreshed brand identity and store designs were completed in partnership with Turner Duckworth, a global design firm with offices in the U.S. and the U.K., and Brand Bureau, a creative agency composed of strategists and designers who invent and interpret brands.
“The cannabis industry is constantly evolving and our brand should adapt alongside it. As we approach the seventh anniversary of the launch of RISE, we are proud to unveil a new retail identity that is reflective of the commitment we have made to our community-based roots and socially inspired mission to improve the cannabis industry for the better. With the newly designed stores, we want patients and customers to feel empowered and supported throughout their RISE experience.” — Jen Denis, vice president of creative services, Green Thumb
Turner Duckworth’s contributions to RISE’s revitalized brand identity were inspired by the upward momentum of the cannabis industry rising into the dawn of a new day. The international design studio used RISE’s optimistic and empowering aesthetic to create a bird-centric brand mark that embodies the healing and transformative qualities of cannabis. The brand mark is accompanied by a bold, vibrant color palette inspired by the cannabis plant and its products, as well as a raw, textured aesthetic that is disruptive and irreverent. The plant inspired the RISE illustration style, which feels natural, bold, layered, textural, and produced by hand — a celebration of the plant.
Advertisement
“Good designs are creative, but great designs are inspired. We are proud to stand alongside a brand like RISE that works tirelessly to elevate the cannabis industry and the world around it. Their purpose-based work greatly inspired our vision for their reimagined brand identity, and we are excited to share it with the world.” — Gavin Hurrell, creative director, Turner Duckworth
Brand Bureau was the interior designer for the RISE prototype design. The design translates the visual identity from Turner Duckworth to the environment by creating signature moments within the customer journey, honouring each region through localized illustrations, and embracing flexibility in the application of design elements to drive this pioneering product market.
“Drawing from our hospitality-industry expertise, our goal was not just to simply translate the visual identity to the interiors but provide a new approach to the design and experience of cannabis retail by creating an approachable and memorable environment that guests would want to return to again and again. The outcome was achieved by activating the brand in large impact and nuanced touchpoints through the thoughtfully considered guest journey.” — Hilary Miners, head of environment design, Brand Bureau
Turner Duckworth is a world-class design firm known for its ability to craft unmistakable visual identities and packaging for trend-forward brands. Brand Bureau is a creative agency comprised of designers and strategists, born out of the award-winning design and concept firm, AvroKO. The branding firm employs a multidisciplinary approach to design that helps companies form meaningful connections with their clients.
Smiths Falls, Ont. — Canopy Growth Corp. says it recorded an almost $42 million net loss in its most recent quarter as it reduced its costs by $47 million.
The Smiths Falls, Ont., cannabis company says its first-quarter net loss compared with a net loss of roughly $2.1 billion a year ago.
The net loss for the three months ended June 30 amounted to a loss of about seven cents per basic and diluted share compared with a loss of $5.24 per basic and diluted share a year ago.
Revenue in the quarter amounted to $121.1 million, up from $118.7 million in the first quarter of the prior fiscal year.
Advertisement
The pot company attributed the increase to higher revenues within its BioSteel business and growth in its Stroz & Bickel brand and the Canadian medical cannabis market.
It says these wins were offset by lower international medical cannabis sales due to bulk sales in Israel and decreased Canadian adult-use business-to-business revenue.
(Globe Newswire) Winnipeg — DELTA 9 CANNABIS INC. has been approved to supply recreational use cannabis products to Northwest Territories Liquor and Cannabis Commission for sale in Northwest Territories.
“This marks Delta 9’s eighth Canadian provincial and territorial supply approval after, Manitoba, Saskatchewan, Alberta, British Columbia, Ontario, Newfoundland and Labrador, and Yukon Territory. We continue to expand our market access domestically and look forward to supplying retail stores and consumers in the Northwest Territories with Delta 9’s premium branded cannabis products.” — Alexa Goertzen, vice president of cannabis sales, Delta 9
The company plans to make its first shipment of cannabis for retail sale in the Northwest Territory in the third quarter of 2023. Delta 9 is in continued discussions with other provinces, territories and private retail outlets and plans to secure additional cannabis supply agreements over the balance of 2023.
Morality – the extent to which an action is right or wrong.
Peggy und Marco Lachmann-Anke from Pixabay” width=”376″ height=”376″>
A working definition of morality indicates what is a “right” or “wrong” way to behave.
Humans experience right and wrong based on the consequences of their actions. When life comes with responsibilities, it makes moral claims on each of us. Moral claims rise to a higher level than the claims of law. Under morality, there are things we must do and things we must not do. Whether these actions are “good” or “bad” is the subject of ethics. Ethics comes from society and the beliefs and values of the collective.
Values are the privileges of a democracy, whereas morals are the rights of a democratic republic.
The fact is that good people can do bad things. People can act in their own self-interest and at the expense of others. If we lose our morals, we are left with values.
The focus on what to wear, how to style your hair, what school to send your kids to, what to drink, what to eat, how to identify yourself— these are values.
Values are judgments and opinions about what is important in life. Everyone has an opinion. Values are sexy!
Building the Hive Mind
A focus on “shared values” keeps people in the zone of groupthink where they conform to a norm, or stand out as the odd duck. By your actions, you are known.
Becoming “average” coalesces everyone from the fringe to the center because being on the fringe is not sexy. With full focus on value judgments and opinions, people may forget morals. But they will be safe.
Creating the path to the center is the job of Social Engineers. The goal is to homogenize the population into a Hive Mind and bring about a state where a foundation of human rights no longer exists. To accomplish this, Social Engineers attempt to create The Great Reset. In this new Age, people will accept less to be more because by 2030 your life savings will not be enough to sustain you. When everything is shared, you will be sustained by the collective.
The conscious and intelligent manipulation of the organized habits and opinions of the masses is an important element in democratic society. – Edward Bernays, Propaganda, 1928
The tone of The Great Reset is summarized by Danish MP Ida Auken in her 2016 essay, also published by promoters at the Summit of the WEF in Davos Switzerland. The Great Reset is marketed and sold as a privileged world of “equality” and “safety” without privacy, because who needs that in a hive?
PollyDot from Pixabay” width=”266″ height=”399″>
In a value-based structure, it is the Queen Bee who directs her subjects. The result is the appearance of equality while actually creating more division among subjects with less power, known as drones.
Social experiments have shown how large groups of people can be influenced as one mind: 1) the 2017 Pussyhat march attracted large numbers of women who marched together wearing pink hats that mocked their sexual organs atop their heads, 2) “White Privilege,” or reverse racism, blamed white people for racism while doing nothing to correct it, 3) “Black Lives Matter” further segregated Black people from all people, 4) “Gender Bending” subdivides male and female genders into 50+ identities, while diagnosing it as a condition known as Gender Dysphoria, and 5) “unvaccinated people” who are asymptomatic are weaponized as a danger to the vaccinated.
Each group, whether white-privilege, Black Lives Matter, Gender Identity, or Unvaccinated, are subdivisions of one humanity. Yet, each time a new narrative is engineered, it creates a new class of people, while distracting from the underlying agenda to further divide and conquer. The new groups serve the Queen as she commands even if they never actually see her. After a season, the message of the movement disappears and is never spoken of again. But the seed of the program remains to be watered with each new movement.
Those who manipulate this unseen mechanism of society constitute an invisible government which is the true ruling power of our country. We are governed, our minds are molded, our tastes formed, our ideas suggested, largely by men we have never heard of. – Edward Bernays, Propaganda, 1928
Values coalesce people to give up their unique “l” identity to a super organism where everyone has the same thoughts, same emotions, and same opinions. They belong to a privileged class. No one thinks to ask if the actions that caused the subdivisions are ‘right’ or ‘wrong.’ Those who think to ask are censored or attacked for being different.
Drones choose an external “cause” to do the thinking for them. Thus, nothing changes internally. There is no moral yardstick for rights or freedom. The only thing that changes is where the Queen directs you next.
Where did this diversion from morals to values begin?
Losing Morality to Consensus
The sciences of Evolutionary Science, Behavioral Science, Neuroscience, Political Science have joined together with Artificial Intelligence to hatch Scientism, the religion of Science that replaces morals and ethics to advance Evolutionary Biology to a new level. The result? The absence of leadership.
A Melbourne-led team has for the first time shown that 800,000 brain cells living in a dish—DishBrain—can perform goal-directed tasks—in this case, the simple tennis-like computer game, Pong. The researchers’ experiments provide evidence that brain cells in a dish can exhibit inherent intelligence, modifying their behavior over time. – Genetic Engineering & Biotechnology News, Oct 2020
Consensus: “The process of abandoning all beliefs, principles, and policies in search of something in which no one believes, but to which no one objects; the process of avoiding the very issues that have to be solved, merely because you cannot get agreement on the way ahead. – Margaret Thatcher, UK Prime Minister
Charles Darwin used Evolutionary Science to make humans believe they descended from bacteria. Yet, this assumption cannot be demonstrated in Nature. If evolution was happening as you read this, you should be able to look outside your window and see the various stages of bacteria advancing into the human form. Thousands of published studies would have documented shared genes between the species.
The moral? Nature does not function under Darwin’s assumptions.
According to the laws of Nature, each species is distinct, separated by a “species barrier.” This barrier protects the integrity of a particular species so that it has a good chance of surviving to produce more of its own kind. This way a zebra doesn’t find a chicken attractive and change its stripes. If a horse mates with a donkey, they produce an infertile mule. The only way to take on a disease from another species is to inject a patented product.
For instance, Swine Flu (H1N1) is listed as a type of infection. It’s called swine flu because it resembles a respiratory infection that pigs can get in crowded conditions, not because humans catch it from pigs. If an infection is a newsworthy, it usually has a viral patent associated with it: ZIKA, EBOLA, SARS, Coronavirus.
Morals represent truth and virtue, whereas science is based on assumptions and conclusions. When we believe science as truth we lose integrity as individuals because we take on other people’s assumptions. We become stiff and rigid in our thinking, and fanatical in our actions. When the unique nature of each individual is melded into a consensus mind, humans become a consensus species.
Not sexy!
Consensus Science
An August 2017 study was published in the Journal of Infectious Diseases to evaluate the difference between artificial immunity via vaccination, and natural immunity via natural infection:
Donated blood was separated into three groups – those who were born before the vaccine was available, those who were born during a time when only one shot was given, and those who were born during a time in which 2 shots were given. Results were dramatic.
The majority of antibodies were observed in the early group, the unvaccinated, who had three more times the antibodies in their blood than those that had received…one shot, and 8 times more than those that had received 2 shots.
The evidence showed natural immunity is sabotaged by artificial interventions. If science had morals, it would call artificial immunity “ineffective and dangerous” to human biological integrity and evolution.
Alas, science derives conclusions, not morals.
Under the structure of science, there is no room for a moral discussion of whether vaccination is good or bad, or right of wrong, for the human species or for any species. The nature of Science is to create endless debate. Thus, when people are mired in debating the science, they are bogged down in value judgments, while morals are lost in the wind. Science as a tool to divide and conquer has done its job.
For those more interested in politics, it works the same way.
Whatever of social importance is done to-day, whether in politics, finance, manufacture, agriculture, charity, education, or other fields, must be done with the help of propaganda. Propaganda is the executive arm of the invisible government. Edward Bernays, Propaganda, 1928
Consensus drives “equality of outcome” which describes fair competition for important jobs and positions so that contenders have equal chances to win such positions. This is illustrated in the novel Alice’s Adventures in Wonderland, when the Dodo tells Alice that “everybody has won and all must have prizes.” More commonly, equality of outcome is seen in Trans Athletics where biological men who identify as women dominate women’s sports.
The problem with this idea? Like evolution, the assumption of equal outcomes does not exist in the Natural world. In a world of individuals, some people are more equal than others. The moral?
A recent study reveals that New York City stands as the global leader in marijuana consumption, surpassing all other cities with an annual intake of 62.3 metric tons, equivalent to around 137,000 pounds. Conducted under the title “2023 Global Marijuana Price Index,” this comprehensive research effort was orchestrated by the CFAH, a reputable source for health-related information. The meticulous data collection spanned 140 urban centers worldwide, analyzing marijuana pricing trends.
The CFAH team closely scrutinized nations at the extremes of marijuana consumption, a criterion that aided in narrowing down the selection of cities for the study. The legal framework for marijuana in each geographical area played a pivotal role in this selection process. Ultimately, 140 cities were singled out to present a comprehensive and insightful global marijuana pricing comparison.
The CFAH relied on WHO data and analytics to capture the overall consumption landscape. Meanwhile, the pricing trends within the United States were modeled using the SARIMA method, which effectively accounts for data trends.
In terms of marijuana consumption, NYC differs from its peers by a large margin. Despite Australia’s official prohibition of marijuana, Sydney came in second with a consumption of 45.7 metric tons per year. Los Angeles, with an annual intake of 36 metric tons, took third place. Rome and Chicago, with 24.9 and 21.8 metric tons each, came in fourth and fifth, respectively. Other cities that were included in the study and made it to the top 20 list include Toronto, Houston, Tokyo, Vienna, Prague, Phoenix, Hamburg, Montreal, Vancouver, Melbourne, Uskudar, Philadelphia, Dublin, Annapolis and Denver.
Tokyo has the highest cannabis prices, commanding a rate of $33.8 per gram. Dublin, Ireland, came in second at $22.50, while Tallinn, Estonia, followed closely with $22.10 per gram. In contrast, Montreal, Canada, boasted the most affordable marijuana, priced at a mere $5.90 per gram. Following at $6 and $6.20 per gram, respectively, were Bangalore, India, and Notre Dame, Canada.
While the prevailing assumption often links legality to increased accessibility and subsequently reduced prices, the study highlights a more nuanced reality. Both the priciest and the most budget-friendly marijuana cities maintained a delicate equilibrium between legal and illegal statuses.
Among the ten cities with the highest marijuana prices, six enforced prohibitions while the remaining four legalized marijuana. Likewise, the cities offering the least expensive marijuana displayed a minor divergence, with six embracing legality and four upholding its illegal status.
These high marijuana consumption rates create openings for entities such as Advanced Container Technologies Inc. (OTC: ACTX) to do brisk business supplying cultivation equipment to the enterprises growing this marijuana for sale on the market.
NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
A judge has approved Organigram’s application for judicial review of Health Canada’s decision that Jolt’s “ingestible extracts” were in contravention of the federal Cannabis Regulations.
The judgement, posted on August 8, states that Organigram’s application for judicial review has been granted. The matter will now be sent back to Health Canada for redetermination, taking the judge’s reasons into consideration.
The filing, posted March 31, 2023, as Organigram Inc. v. Minister of Health et al., falls under Section 18.1 Application for Judicial Review. Judicial review is a process by which the courts can ensure that the decisions of administrative bodies like Health Canada are fair, reasonable, and lawful.
However, when all of the circumstances of the case are taken into account… I find that there was a breach of procedural fairness arising from inadequate notice of Health Canada’s reliance on a factor contained in the Compliance Promotion Statement and, as a result, that Organigram was not afforded a meaningful opportunity to respond to that concern and thereby prejudiced in its ability to respond to that concern.
Judge Cecily Y. Strickland, Organigram Inc. v. Minister of Health et al.
Organigram was seeking a judicial review following Health Canada’s move to end the production and sale of so-called “edible extracts” earlier this year. The company is one of a handful producing products in this category that were packaged exceeding the federal limit of 10mg THC per package for edibles. These were generally in the form of lozenges and gummies.
The company had hoped to see Health Canada’s order quashed or set aside, instead requiring Health Canada to determine that its Jolts lozenges are a cannabis extract and do not constitute edible cannabis under the Regulations.
Organigram and others who have made these products contend they are compliant products.
In early January 2023, Health Canada sent a notice to producers highlighting their concerns with these products. Companies were told they had until May 31, 2023, to cease sales and distribution.
Organigram, which has been selling its Edison Jolts products as cannabis-infused lozenges in packaging exceeding 10mg THC, said in March that it had paused production. It maintained that the products were compliant with federal regulations.
Health Canada issued a public warning about these products on March 3.
“Some edible cannabis products were found to contain more than the allowable limit of 10mg of THC per package,” notes the press release. “These non-compliant products in product formats similar to gummies and other confectionery products, such as hard candy, have been incorrectly marketed and sold as cannabis extracts.”
The federal health authority also issued a new online document providing clarity on the issue of the classification of edible cannabis. The document, in part, notes that a cannabis edible is defined as any article manufactured, sold, or represented for use as food or drink for human beings, chewing gum, or any ingredient that may be mixed with food for any purpose.
Although Organigram had argued that Health Canada’s decision that their edible or “ingestible” extract products weren’t compliant was incorrect, the judge disagreed. Instead, the judge ruled that the federal health agency’s process to reach that conclusion was not fair and deserved further analysis.
The judge ruled that the unfairness of Health Canada’s decision on the ingestible extracts was, in part, due to it including additional factors in its decision-making process that Ogranigram was not provided an opportunity to respond to.
For example, court records show that Health Canada introduced a “fourth factor” in the decision that was omitted from the Notice of Non-Compliance that it issued to Organigram. The judge argued this factor—the product’s sensory and physical characteristics—is not found in Health Canada’s Guidance Document because Organigram was not given an opportunity to respond to Health Canada’s objection to the Jolts’ size and shape or suitability for sublingual and buccal absorption.
Organigram was not afforded a meaningful opportunity to respond to that concern and thereby prejudiced in its ability to respond to that concern,” wrote the judge in their analysis.
“Given my finding that Health Canada breached the duty of procedural fairness by relying on a product classification factor found only in the Compliance Promotion Statement, which was published after the decision was issued, I need not address Organigram’s further procedural fairness submission based on delay, nor the submissions as to the reasonableness of the decision,” concluded judge Cecily Y. Strickland.
“I am satisfied that a lower level of procedural fairness was owed to Organigram and that several opportunities to respond were provided to it throughout the decision-making process, with which Organigram engaged,” the judge also wrote in their ruling. “However, when all of the circumstances of the case are taken into account… I find that there was a breach of procedural fairness arising from inadequate notice of Health Canada’s reliance on a factor contained in the Compliance Promotion Statement and, as a result, that Organigram was not afforded a meaningful opportunity to respond to that concern and thereby prejudiced in its ability to respond to that concern.”
The case will now go back to Health Canada for their opportunity to respond.
Health Canada initially issued warnings to some producers or manufacturers of so-called “edible extracts” in January, warning them they were not compliant with federal regulations. One producer, Vortex Cannabis, confirmed they received an order from Health Canada to stop sales of their Full Spectrum THC Jelly Cubes due to these being inaccurately classified as extracts rather than edibles.
The Vortex Jelly Cubes came in 10mg THC squares, sold with multiple units per pack.
The court documents also reference the Vortex Jelly Cubes, which caused one woman to be taken to hospital where she was told she had overdosed on cannabis after consuming several of the product, assuming they contained only 10mg THC for the entire container, rather than 100mg THC.
A recent study published in the “Psychedelic Medicine” journal has reported that psilocybin possesses effects akin to antidepressants and may alleviate cognitive deficits resulting from chronic stress in animal models. Psilocybin is a hallucinogenic compound produced in magic mushrooms. Although it has been used recreationally for decades because of its hallucinatory effects, a growing body of research now shows that psilocybin may also have a myriad of mental health benefits.
This research has found that psilocybin as well as other psychedelic compounds such as LSD and ayahuasca can treat various mental-health conditions, offering relatively long-term relief at low doses and with barely any side effects. However, most of the research is still in its infancy, and researchers barely understand the underlying mechanisms that allow psychedelics to deliver mental-health benefits.
In the recent psilocybin study, researchers used an animal model of female rats to inquire into the molecular and cellular mechanisms behind the antidepressant-like effects of hallucinogenics such as psilocybin. Since chronic stress plays a major role in the development of depression, the team leveraged a model focusing on chronic stress and chose female rats since women are more predisposed to depression than men.
Using an adolescent chronic restraint stress (aCRS) model, the researchers induced depression-like symptoms in the rats during key developmental stages such as adolescence to ensure they remained into the rats’ adulthood. The aCRS model caused depressive-like symptoms, including behavioral and cognitive defects, as well as temporary reductions in weight gain by the rats.
After receiving a psilocybin dose, the rats showed increased cognitive functioning and a reduction in the coping strategies they used to deal with depression, indicating that psilocybin has antidepressant effects in animal models. Additional analysis into the regions of the brain involved in depression found that the hippocampus as well as medial prefrontal cortex played key roles in psilocybin delivering antidepressant effects.
The research team posits that those cognitive deficits seen after chronic stress may occur because of functional brain changes instead of significant structural differences. Furthermore, they say that psychedelics may deliver their effects by encouraging functional plasticity and promoting changes in the way cells in the brain communicate and not through promoting structural plasticity, which causes physical brain cell connections to change.
The researchers concluded that functional plasticity rather than structural plasticity may be the key underlying mechanism behind psilocybin’s antidepressant effects, contradicting prior psychedelic research, which ties structural plasticity to hallucinogenics’ antidepressant-like effects. Future research will be necessary to fully understand the underlying mechanisms that allow psychedelics to alleviate depression and how to leverage them to develop depression treatments.
As more entities such as Field Trip Health Ltd. (OTC: FTHWF) (TSX: FTHW) conduct studies into the therapeutic potential of psilocybin, much more will become known about how this and other psychedelics work to address mental health issues.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
Peggy und Marco Lachmann-Anke from Pixabay” width=”376″ height=”376″>
PollyDot from Pixabay” width=”266″ height=”399″>
Donated blood was separated into three groups – those who were born before the vaccine was available, those who were born during a time when only one shot was given, and those who were born during a time in which 2 shots were given. Results were dramatic.
Recent Comments